Pathology-targeted EP4 agonism resolves fibrosis and restores regeneration in a rat model of adolescent Duchenne muscular dystrophy

Authors
Nasim Kajabadi, Ashok Narasimhan, Gang Chen, Lin Yi, Cristina Rodríguez-Rodríguez, Ian F. Coccimiglio, Tiffany Huang, Mariana Rendeiro, Keitaro Yamanouchi, Urs O. Häfeli, Paul Kostenuik, Robert N. Young, Fabio M.V. Rossi


Lab
UBC; 2 UBC; Berkeley

Journal
bioRxiv

Abstract

Abstract

Duchenne muscular dystrophy (DMD) presents a critical therapeutic gap in adolescent patients, where extensive fibro-fatty muscle replacement and depletion of the regenerative niche render existing interventions insufficient. Prostaglandin E2 signaling through the EP4 receptor stimulates bone and muscle regeneration and repair, but systemic off-target effects have limited the clinical translation of EP4 agonism in diseases such as DMD. We therefore evaluated irodanoprost (IROD), a bone-targeted prodrug of an EP4-selective agonist, in a DMD rat model, comparing early- and late-intervention cohorts. In adolescent rats, 8 weeks of treatment reduced body weight deficit by 41.4% and restored hindlimb muscle mass and maximum tetanic force to wild-type levels. IROD dose-dependently inhibited fibro-adipogenic progenitor differentiation into α-SMA⁺ myofibroblasts, facilitating active resolution of established fibrosis below pre-treatment baseline. This was accompanied by re-activation of a synchronized regenerative program marked by clustered eMHC⁺ fibers, restoring the total myofiber pool to wild-type levels. A strong linear correlation between intramuscular fat reduction and fibrosis resolution suggests that MRI-based fat imaging may serve as a non-invasive surrogate for monitoring anti-fibrotic efficacy. The efficacy of IROD is likely aided by the fact that while it selectively distributes to bone in healthy animals, we observed markedly enhanced accumulation of the drug in dystrophic muscle. These findings establish IROD as a pathology-targeted approach capable of resolving the fibro-fatty niche and restoring regenerative capacity in advanced DMD.

Summary

Pathology-targeted EP4 agonism resolves established fibrosis and restores myofiber regeneration in a rat model of adolescent Duchenne dystrophy.

Graphic abstract

Keywords/Topics
regeneration; bone and muscle regeneration; adolescent rats; regenerative capacity; myofiber regeneration; four-limb grip strength testing; pathology-targeted ep4 agonism; fibrosis; adolescent duchenne muscular dystrophy; adolescent patients

Source :

https://www.biorxiv.org/content/10.64898/2026.05.29.728674.abstract

Produits associés

Test d'agrippement

DEMANDE DE PUBLICATION

Merci de votre intérêt pour notre gamme de produits et de votre demande pour cette publication qui vous sera envoyée si l'équipe de recherche et la revue le permettent. Notre équipe commerciale vous contactera dans les plus brefs délais.